If validated, a patient-specific ctDNA assay for residual disease after neoadjuvant therapy could bring an end to the surgery-for-all approach in breast cancer.
Helen Leask, PhDhttp://www.visionworkshop.ca
Helen Leask, PhD, CPF, is a freelance science journalist and certified facilitator. She was a 2018-2019 fellow in global journalism at the Munk School of Global Affairs, University of Toronto, Canada. Her journalistic beats are oncology and human factors in medicine. Her work has appeared on the CBC and in Medscape, Maclean's, Quartz, The Globe and Mail, Xtalks, and The Walrus. Helen worked as a researcher and science writer in the U.K. In Canada, she founded 3 creative companies, including a medical book publisher, a patient-research company, and an award-winning Toronto health care communications agency that she ran for almost 20 years before selling the company in the summer of 2017. Her book-publishing label has published 12 books for patients, most recently, The Canadian Guide to Prostate Cancer, 2nd Edition. In 2006, Helen founded The SCRIPT Award, an international writing award for science graduates. Helen has a PhD in zoology from the University of Bristol. She is currently a remote adjunct professor at the San Diego Biomedical Research Institute, an occasional lecturer in science communications at Laurentian University, and a patient reviewer for the British Medical Journal.